

**South East London Area Prescribing Committee
Formulary recommendation**

Reference	039
Intervention:	Depot medroxyprogesterone acetate 104 mg/0.65 ml suspension (SAYANA PRESS®) for sub-cutaneous injection for long-term female contraception Sayana Press® is a progesterone only, long acting injectable depot contraceptive.
Date of Decision	October 2015
Date of Issue:	November 2015
Recommendation:	GREEN – can be prescribed within agreed criteria for use in primary or secondary care
Further Information	<ul style="list-style-type: none"> • Depot medroxyprogesterone acetate (DMPA) sub-cutaneous injection (Sayana Press®) is accepted for use in SEL as a long acting contraceptive in women where a parenteral preparation of depot medroxyprogesterone would be considered as a contraceptive option. • In particular, Sayana Press® may be preferable for the following groups of women where the intramuscular route of administration may not be suitable: <ul style="list-style-type: none"> - Women at risk of haematoma due to bleeding disorders or anticoagulation. - Women who are very obese for whom there is concern about intramuscular DMPA reaching muscle. • In line with the Summary of Product Characteristics for Sayana Press®, administration of the product should be initiated under the supervision of a healthcare professional. • After proper training in injection technique and schedule of administration, patients may self-inject if their healthcare professional determines that it is appropriate and with medical follow-up as necessary. • The injections should be given at 13 week intervals. • From the available evidence DMPA for sub-cutaneous injection is as efficacious as DMPA for intramuscular injection and appears to have a similar adverse effect profile.
Shared Care/Transfer of care document required:	N/A
Cost Impact for agreed patient group	<ul style="list-style-type: none"> • The cost of one sub-cutaneous DMPA injection (Sayana Press®) is £6.90, this compares to £6.01 for one intramuscular DMPA injection (Depo-Provera®, 12 weekly injection). This equates to £27.60 and £26.04 per patient per year respectively for each preparation. • In comparison oral contraceptive options vary in price from £7.60 to £40 per patient per year • Sayana Press will be considered for patients who opt for a parenteral, progesterone only long acting reversible contraceptive. Around 5% of patients currently opt for intramuscular DMPA and Sayana Press would be the alternative option in these patients. • Based on prescribing of intramuscular DMPA by sexual health clinics in two SEL boroughs in the last 12 months: if sub-cutaneous DMPA replaced intramuscular DMPA, this would equate to an additional cost impact of £3,560 per annum. Extrapolating this to SEL would result in a total additional cost impact of ~£11,000. • For every £1 spent on switching from oral contraception to long acting reversible contraception, £10 is saved by the health economy by preventing unintended pregnancies.

Usage Monitoring & Impact Assessment	CCGs to liaise with Local Authorities regarding this recommendation where relevant for local contraceptive services and to monitor impact data.
Evidence reviewed	<p>References (from evidence evaluation):</p> <ol style="list-style-type: none"> 1. NICE Evidence Summary New Medicine: Long acting reversible contraception: subcutaneous depot medroxyprogesterone acetate. January 2014. 2. NICE Clinical Guideline 30: Long-acting reversible contraception. August 2015 update. 3. Health and Social Care Information Centre (2013) NHS contraceptive services: Englan 2012/13: community contraceptive clinics. 4. Kaunitz A, Darney P, Ross D et al. Subcutaneous DMPA vs intramuscular DMPA: a 2 year randomised study of contraceptive efficacy and bone mineral density. <i>Contraception</i> 2009 80 p7-17. 5. Jain J, Jakimiuk A, Bode F et al. Contraceptive efficacy and safety of DMPA subcutaneous <i>Contraception</i> 2004 70 p269-275. 6. European Medicines Agency 2005. Guideline on clinical investigation of steroid contraceptives in women. Doc. Ref EMEA/CPMP/EWP/519/98 Rev 1. 7. Medicines and Healthcare Products Regulatory Agency (2011). Sayana Press 104mg/0.65ml suspension for injection PL00057. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con088109.pdf <accessed on 14/09/2015> 8. Summary of Product Characteristics: Sayana Press. Available at: http://www.medicines.org.uk/emc/medicine/27798 <accessed on 14/09/2015> 9. Westhoff C, Jain J, Milsom I et al. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104mg/0.65ml. <i>Contraception</i> 2007 75 p261-267. 10. Faculty of Sexual and Reproductive Healthcare (June 2013). Subcutaneous depot medroxyprogesterone acetate (Sayana Press) – New Product Review from the Clinical Effectiveness Unit. 11. Summary of Product Characteristics: Dep-Provera 150mg/ml injection. Available at: http://www.medicines.org.uk/emc/medicine/11121 <accessed on 14/09/2015> 12. British National Formulary March 2015. Available at: www.medicinescomplete.com <accessed on 14/09/2015> 13. National Cost-Impact Report for implementing the NICE clinical guideline for long acting reversible contraception (NG30) December 2005. Available online at: http://www.nice.org.uk/guidance/cg30/resources/longacting-reversible-contraception-cost-impact-report2 <accessed on 01.10.2015>

NOTES:

- a) Area Prescribing Committee recommendations and minutes are available publically on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- c) **Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**